Your browser doesn't support javascript.
loading
Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial.
Rahhal, Alaa; Najim, Mostafa; Aljundi, Amer Hussein; Mahfouz, Ahmed; Alyafei, Sumaya Mehdar; Awaisu, Ahmed; Habib, Mhd Baraa; Obeidat, Ibrahim; Faisal, Mohanad Mohammed; Alanzi, Meshaal Ali; Nair, Arun Prabhakaran; Elhassan, Areeg; Al-Dushain, Abdullah; Abdelmajid, Alaaeldin Abdelmajid; Abdelgader, Ahmed Elfadil; Moursi, Ahmed Mahmoud Ahmed; Alharafsheh, Ahmad Eid Nazzal; Kamar, Mohd Ragheb Abou; Goravey, Wael; Omar, Amr Salah; Abukhattab, Mohammed; Khatib, Mohamad Yahya; Mohamedali, Mohamed Gaafar; AlMaslamani, Muna A Rahman; Alemadi, Samar.
Afiliação
  • Rahhal A; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
  • Najim M; Internal Medicine Department, Rochester Regional Health - Unity Hospital, NY, USA.
  • Aljundi AH; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
  • Mahfouz A; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
  • Alyafei SM; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
  • Awaisu A; College of Pharmacy, Qatar University, Doha, Qatar.
  • Habib MB; Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
  • Obeidat I; Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
  • Faisal MM; Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
  • Alanzi MA; Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
  • Nair AP; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Elhassan A; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Al-Dushain A; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Abdelmajid AA; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Abdelgader AE; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Moursi AMA; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
  • Alharafsheh AEN; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
  • Kamar MRA; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Goravey W; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Omar AS; Cardiothoracic Surgery/Cardiac Anaesthesia Department, Hamad Medical Corporation, Doha, Qatar.
  • Abukhattab M; Cardiothoracic Surgery/Cardiac Anaesthesia Department, Hamad Medical Corporation, Doha, Qatar.
  • Khatib MY; Medical Intensive Care Department, Hamad Medical Corporation, Doha, Qatar.
  • Mohamedali MG; Internal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
  • AlMaslamani MAR; Infectious Diseases Department, Hamad Medical Corporation, Doha, Qatar.
  • Alemadi S; Rheumatology Department, Hamad Medical Corporation, Doha, Qatar.
Medicine (Baltimore) ; 101(39): e30618, 2022 Sep 30.
Article em En | MEDLINE | ID: mdl-36181009
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 4_TD Problema de saúde: 1_doencas_nao_transmissiveis / 4_covid_19 / 4_pneumonia Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Prognostic_studies / Qualitative_research Aspecto: Ethics Limite: Humans Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Qatar
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 4_TD Problema de saúde: 1_doencas_nao_transmissiveis / 4_covid_19 / 4_pneumonia Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Prognostic_studies / Qualitative_research Aspecto: Ethics Limite: Humans Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Qatar